Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer

Bozinovski, S; Vannitamby, A; Rangamuwa, K; Aujla, S; Wang, H; Aloe, C; Irving, L; Leong, TT; Steinfort, DP

Author(s): Bozinovski, S; Vannitamby, A; Rangamuwa, K; Aujla, S; Wang, H; Aloe, C; Irving, L; Leong, TT; Steinfort, DP;
Details: Publication Year 2021,Volume 10,Issue #6,Page 2779-2787
Journal Title: Translational Lung Cancer Research
Abstract: Immunotherapy has transformed treatment of advanced non-small-cell lung cancer (NSCLC) patients leading to remarkable long-term survival benefit. However, only about 20% of advanced NSCLC patients typically respond to immune checkpoint inhibitors (ICIs) that target the PD-1/PD-L1 pathway. The only validated biomarker for ICI therapy is the PD-L1 immunohistochemistry (IHC) test, which is considered an imperfect assay due to several variables including availability and integrity of tumour tissue, variability in staining/scoring techniques and heterogeneity in PD-L1 protein expression within and across tumour biopsies. Herein, we discuss integrating minimally invasive EBUS bronchoscopy procedures with novel molecular approaches to improve accuracy and sensitivity of PD-L1 testing. EBUS guided bronchoscopy facilitates repeated sampling of tumour tissue to increase the probability of detecting PD-L1 positive tumours. Since intra-tumoural PD-L1 (CD274) copy number is reported to be less heterogeneous than PD-L1 protein detection, quantifying PD-L1 transcript levels may increase detection of PD-L1 positive tumours. PD-L1 transcript levels show excellent concordance with PD-L1 IHC scoring and multiplex digital droplet PCR (ddPCR) assays that quantify absolute PD-L1 transcript copy number have been developed. ddPCR can also be automated for high throughput detection of low abundant variants with excellent sensitivity and accuracy to improve the broader application of diagnostic cut-off values. Optimizing diagnostic workflows that integrate optimal EBUS bronchoscopy procedures with emerging molecular ICI biomarker assays may improve the selection criteria for ICI therapy benefit. © 2021 AME Publishing Company. All rights reserved.
Publisher: AME Publishing Company
Keywords: Biomarkers; Bronchoscopy; Immunotherapy; Lung cancer; Non-small cell lung cancer (NSCLC); Programmed death Inhibitor 1 ligand (PD-L1)
Research Division(s): Personalised Oncology
Publisher's Version: https://doi.org/10.21037/tlcr-20-781
Open Access at Publisher's Site: https://doi.org/10.21037/tlcr-20-781
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2021-07-20 11:17:57

Last Modified: 2021-07-20 11:20:38